Akshat Jain
Pediatric Hematology-Oncology · Redlands, CANPI 1700150885
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $275,423 of the $447,094 with a category attached, or 61.6%. 23 manufacturers reported payments, led by Sanofi at 40.6% of the total. 2025 is the largest year on record at $223,389, more than ten times the $7,705 reported in 2019. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $1292.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$181K
- Pfizer$91K
- Novo Nordisk$75K
- Octapharma USA, Inc.$24K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- Sanofi US Services Inc.$15K
- plus $42K from 17 others
Across 41 payments — averaging $3439.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$44K
- Sanofi US Services Inc.$41K
- Octapharma USA, Inc.$33K
- Bioverativ Therapeutics Inc.$23K
What the payments were for
- Consulting fees$106,96624%
- Speaking & faculty fees$275,42362%
- Travel & lodging$57,25913%
- Food & beverage$7,2982%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 84 | $181,364 |
| Pfizer | 73 | $91,156 |
| Novo Nordisk | 53 | $75,384 |
| Octapharma USA, Inc. | 53 | $24,422 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $18,130 |
| Sanofi US Services Inc. | 1 | $14,718 |
| Bayer | 15 | $13,691 |
| Global Blood Therapeutics, Inc. | 9 | $7,919 |
| CSL Behring | 8 | $6,528 |
| Sanofi-aventis U.S. LLC | 4 | $4,556 |
| Dova Pharmaceuticals | 1 | $3,080 |
| Shire North American Group Inc | 12 | $2,031 |
| Bioverativ Therapeutics Inc. | 2 | $1,954 |
| Cerus Corporation | 4 | $595 |
| Novo Nordisk Health Care AG | 1 | $375 |
| Cardinal Health 110 LLC | 1 | $300 |
| Agios Pharmaceuticals, Inc. | 3 | $229 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| Biomarin Pharmaceutical Inc. | 1 | $136 |
| Novartis | 2 | $134 |
| Genentech, Inc. | 3 | $120 |
| Genentech USA, Inc. | 1 | $80 |
| Vertex | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTUVIIIO$127,685
- HYMPAVZI$72,108
- QFITLIA$23,723
- Alhemo$17,249
- NovoSeven$16,631
- OXBRYTA$15,753
- WAYRILZ$13,297
- NUWIQ$10,675
- Jivi$8,972
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$6,379
- ADVATE$5,510
- Esperoct$4,500
- FIBRYGA & BALFAXAR$4,406
- NO PRODUCT DISCUSSED$4,381
- Afstyla$3,360
- DOPTELET$3,080
- REBINYN$1,834
- Idelvion$1,713
- ADYNOVATE$1,600
- BENEFIX$1,350
How this compares
$447,094 in reported general payments places this provider in the 95th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Redlands
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
- Arash MahajerinOrange$249K
- Elysia AlvarezPalo Alto$200K
- Christopher DvorakPalo Alto$144K
- Jan van TornoutLos Angeles$137K
- Courtney ThornburgSan Diego$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.